Impact of Availability of Companion Diagnostics on the Clinical Development of Anticancer Drugs
Crossref DOI link: https://doi.org/10.1007/s40291-017-0267-y
Published Online: 2017-02-28
Published Print: 2017-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Tibau, Ariadna
Díez-González, Laura
Navarro, Beatriz
Galán-Moya, Eva M.
Templeton, Arnoud J.
Seruga, Bostjan
Pandiella, Atanasio
Amir, Eitan
Ocana, Alberto
Funding for this research was provided by:
CRIS Cancer, ISCIII, ACEPAIN
License valid from 2017-02-28